Calmodulin-binding transcription activator 1 (CAMTA1)

Homo sapiens — UniProt Q9Y6Y1

Gene: CAMTA1Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

Calmodulin-binding transcription activator 1 (CAMTA1) is a protein from Homo sapiens identified by UniProt accession Q9Y6Y1, 1673 residues long. MolForge cross-references it against 0 known binders and 261 disease associations.

UniProt accession: Q9Y6Y1; gene symbol CAMTA1.
Organism: Homo sapiens.
Length: 1673 amino acids.
Top disease associations (Open Targets): cerebellar dysfunction with variable cognitive and behavioral abnormalities, Non-progressive cerebellar ataxia with intellectual disability and genetic disorder.
3D structure: AlphaFold model available.

Target properties

Protein name	Calmodulin-binding transcription activator 1
UniProt accession	Q9Y6Y1
Gene	CAMTA1
Organism	Homo sapiens
Length	1673 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (261)

Diseases linked to this target (Open Targets).

cerebellar dysfunction with variable cognitive and behavioral abnormalities · score 0.78
Non-progressive cerebellar ataxia with intellectual disability · score 0.74
genetic disorder · score 0.50
prostate adenocarcinoma · score 0.40
Intellectual disability · score 0.39
mathematical ability · score 0.38
self reported educational attainment · score 0.38
appendicular lean mass · score 0.38
breast ductal adenocarcinoma · score 0.37
pancreatic carcinoma · score 0.37

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q9Y6Y1-F1	alphafold	PREDICTED	50.63	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y6Y1.

Amino-acid sequence (1673 residues)

MWRAEGKWLP KTSRKSVSQS VFCGTSTYCV LNTVPPIEDD HGNSNSSHVK IFLPKKLLEC LPKCSSLPKE RHRWNTNEEI AAYLITFEKH EEWLTTSPKT RPQNGSMILY NRKKVKYRKD GYCWKKRKDG KTTREDHMKL KVQGVECLYG CYVHSSIIPT FHRRCYWLLQ NPDIVLVHYL NVPAIEDCGK PCGPILCSIN TDKKEWAKWT KEELIGQLKP MFHGIKWTCS NGNSSSGFSV EQLVQQILDS HQTKPQPRTH NCLCTGSLGA GGSVHHKCNS AKHRIISPKV EPRTGGYGSH SEVQHNDVSE GKHEHSHSKG SSREKRNGKV AKPVLLHQSS TEVSSTNQVE VPDTTQSSPV SISSGLNSDP DMVDSPVVTG VSGMAVASVM GSLSQSATVF MSEVTNEAVY TMSPTAGPNH HLLSPDASQG LVLAVSSDGH KFAFPTTGSS ESLSMLPTNV SEELVLSTTL DGGRKIPETT MNFDPDCFLN NPKQGQTYGG GGLKAEMVSS NIRHSPPGER SFSFTTVLTK EIKTEDTSFE QQMAKEAYSS SAAAVAASSL TLTAGSSLLP SGGGLSPSTT LEQMDFSAID SNKDYTSSFS QTGHSPHIHQ TPSPSFFLQD ASKPLPVEQN THSSLSDSGG TFVMPTVKTE ASSQTSSCSG HVETRIESTS SLHLMQFQAN FQAMTAEGEV TMETSQAAEG SEVLLKSGEL QACSSEHYLQ PETNGVIRSA GGVPILPGNV VQGLYPVAQP SLGNASNMEL SLDHFDISFS NQFSDLINDF ISVEGGSSTI YGHQLVSGDS TALSQSEDGA RAPFTQAEMC LPCCSPQQGS LQLSSSEGGA STMAYMHVAE VVSAASAQGT LGMLQQSGRV FMVTDYSPEW SYPEGGVKVL ITGPWQEASN NYSCLFDQIS VPASLIQPGV LRCYCPAHDT GLVTLQVAFN NQIISNSVVF EYKARALPTL PSSQHDWLSL DDNQFRMSIL ERLEQMERRM AEMTGSQQHK QASGGGSSGG GSGSGNGGSQ AQCASGTGAL GSCFESRVVV VCEKMMSRAC WAKSKHLIHS KTFRGMTLLH LAAAQGYATL IQTLIKWRTK HADSIDLELE VDPLNVDHFS CTPLMWACAL GHLEAAVVLY KWDRRAISIP DSLGRLPLGI ARSRGHVKLA ECLEHLQRDE QAQLGQNPRI HCPASEEPST ESWMAQWHSE AISSPEIPKG VTVIASTNPE LRRPRSEPSN YYSSESHKDY PAPKKHKLNP EYFQTRQEKL LPTALSLEEP NIRKQSPSSK QSVPETLSPS EGVRDFSREL SPPTPETAAF QASGSQPVGK WNSKDLYIGV STVQVTGNPK GTSVGKEAAP SQVRPREPMS VLMMANREVV NTELGSYRDS AENEECGQPM DDIQVNMMTL AEHIIEATPD RIKQENFVPM ESSGLERTDP ATISSTMSWL ASYLADADCL PSAAQIRSAY NEPLTPSSNT SLSPVGSPVS EIAFEKPNLP SAADWSEFLS ASTSEKVENE FAQLTLSDHE QRELYEAARL VQTAFRKYKG RPLREQQEVA AAVIQRCYRK YKQYALYKKM TQAAILIQSK FRSYYEQKKF QQSRRAAVLI QKYYRSYKKC GKRRQARRTA VIVQQKLRSS LLTKKQDQAA RKIMRFLRRC RHSPLVDHRL YKRSERIEKG QGT

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with CAMTA1?

The strongest Open Targets associations for CAMTA1 are cerebellar dysfunction with variable cognitive and behavioral abnormalities, Non-progressive cerebellar ataxia with intellectual disability, genetic disorder, prostate adenocarcinoma and Intellectual disability.

How long is the CAMTA1 protein?

The Homo sapiens CAMTA1 protein (UniProt Q9Y6Y1) is 1673 amino acids long.

Browse: Targets: C · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB Q9Y6Y1 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB Q9Y6Y1 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.